146 related articles for article (PubMed ID: 25083896)
1. Risk assessment for epithelial ovarian cancer: proposing a new approach to a deadly problem.
Chu MM; Fishman D
Scand J Clin Lab Invest Suppl; 2014; 244():63-7; discussion 66-7. PubMed ID: 25083896
[TBL] [Abstract][Full Text] [Related]
2. The potential for risk stratification in the management of ovarian cancer risk.
Pharoah PD
Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S16-7. PubMed ID: 22543912
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic biomarkers in epithelial ovarian cancer.
Gloss BS; Samimi G
Cancer Lett; 2014 Jan; 342(2):257-63. PubMed ID: 22245949
[TBL] [Abstract][Full Text] [Related]
4. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G; Duffy MJ; Othman Abu Hassan S; Verheijen RH; Tholander B; Bast RC; Gaarenstroom KN; Sturgeon CM; Bonfrer JM; Petersen PH; Troonen H; CarloTorre G; Kanty Kulpa J; Tuxen MK; Molina R
Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
[TBL] [Abstract][Full Text] [Related]
5. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
[TBL] [Abstract][Full Text] [Related]
6. Current clinical use of biomarkers for epithelial ovarian cancer.
Moore RG; Maclaughlan S
Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.
Tas F; Kilic L; Bilgin E; Keskin S; Sen F; Ciftci R; Yildiz I; Yasasever V
Int J Gynecol Cancer; 2013 Feb; 23(2):276-81. PubMed ID: 23266651
[TBL] [Abstract][Full Text] [Related]
8. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
Temkin SM; Miller EA; Samimi G; Berg CD; Pinsky P; Minasian L
Eur J Cancer; 2017 Dec; 87():182-188. PubMed ID: 29156299
[TBL] [Abstract][Full Text] [Related]
9. Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Rohr I; Braicu EI; En-Nia A; Heinrich M; Richter R; Chekerov R; Dechend R; Heidecke H; Dragun D; Schäfer R; Gorny X; Lindquist JA; Brandt S; Sehouli J; Mertens PR
Cytokine; 2016 Sep; 85():157-64. PubMed ID: 27371774
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
11. Early detection and screening for ovarian cancer.
Schwartz PE; Chambers JT; Taylor KJ
J Cell Biochem Suppl; 1995; 23():233-7. PubMed ID: 8747402
[TBL] [Abstract][Full Text] [Related]
12. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling.
Zhang H; Ge T; Cui X; Hou Y; Ke C; Yang M; Yang K; Wang J; Guo B; Zhang F; Lou G; Li K
Mol Biosyst; 2015 Feb; 11(2):516-21. PubMed ID: 25424060
[TBL] [Abstract][Full Text] [Related]
13. HE4 in the differential diagnosis of ovarian masses.
Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
[TBL] [Abstract][Full Text] [Related]
14. Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in Patients with Epithelial Ovarian Cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Adv Exp Med Biol; 2016; 924():3-8. PubMed ID: 27753009
[TBL] [Abstract][Full Text] [Related]
15. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
16. Inherited risk of ovarian cancer and the implications for screening.
Gayther SA
Int J Gynecol Cancer; 2012 May; 22 Suppl 1():S12-5. PubMed ID: 22543911
[TBL] [Abstract][Full Text] [Related]
17. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
[TBL] [Abstract][Full Text] [Related]
18. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer.
Kim K; Ruhaak LR; Nguyen UT; Taylor SL; Dimapasoc L; Williams C; Stroble C; Ozcan S; Miyamoto S; Lebrilla CB; Leiserowitz GS
Cancer Epidemiol Biomarkers Prev; 2014 Apr; 23(4):611-21. PubMed ID: 24557531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
